Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1

Interventions

Androgen Antagonists 9darolutamide 6Magnetic Resonance Spectroscopy 6enzalutamide 5apalutamide 5Docetaxel 5Specimen Handling 4Radiotherapy 4Abiraterone Acetate 4Prednisone 3Electroacupuncture 3Brachytherapy 3pembrolizumab 2Standard of Care 2Resistance Training 2Radiosurgery 2Radiation 2Pluvicto 2Interviews as Topic 2Gonadotropin-Releasing Hormone 2Glutamate Carboxypeptidase II 2Bone Density 2Absorptiometry, Photon 2testosterone 17 beta-cypionate 1relugolix 1perflutren 1olaparib 1luprolide acetate gel depot 1fluciclovine F-18 1fezolinetant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Prostatic Neoplasms × Rifaximin × Clear all
NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Mansoura University

Phase 1/2 Not yet recruiting
80 enrolled
GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡